Barchart1d agoneutral
Why DataMEDS’ Acquisition Does Not Seem to Be Very Bullish for MEDS Stock at This PointThe low purchase price of Helomics and low revenue suggest that the acquisition is not that promising for DataMEDS AI.
News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
41last 24h
969last 7d
108● bullish (7d)
121● bearish (7d)
212publishers
24/7 Wall St.39d agobullish
The Biggest IPO of the Year Is Targeted in the Next 60 Days. Why One Unexpected Industry Could Rally Before Then (Hint: It’s Not Tech)Anthropic is racing toward a public debut in September with a healthcare AI pitch that could ignite a sector most investors are not watching. Five biotech names are already moving, and one has climbed nearly 400% in the past year alone.